Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Skeletal metastases often occur in men with castration-resistant prostate cancer (CRPC) where bone biomarkers are prognostic for overall survival (OS). In those with highly elevated markers, there is preferential benefit from bone-targeted therapy. In the phase IIIS0421 docetaxel +/- atrasentan trial, clinical covariates and bone biomarkers were analyzed to identify CRPC subsets with differential outcomes.

Markers of bone resorption [N-telopeptide-NTx; pyridinoline-PYD] and formation [C-terminal collagen propeptide-CICP; bone alkaline phosphatase-BAP] were measured in pre-treatment sera. Bone biomarkers and clinical covariates were included in a Cox model for OS; bone markers were added in a stepwise selection process. Receiver operating characteristic (ROC) curves were constructed for risk factor models +/- bone markers. Significant variables were allowed to compete in a classification and regression tree (CART) analysis. Hazard ratios(HR) were calculated by comparing OS in each of the terminal nodes to a reference group in a Cox model.

750 patients were included. Each bone marker significantly contributed to the risk factor-adjusted OS Cox model, with higher levels associated with worse OS. BAP (HR = 1.15, p = 0.008), CICP (HR = 1.27, p < 0.001), and PYD (HR = 1.21, p = 0.047) in combination were significantly associated with OS. Prognostic accuracy was improved by addition of bone markers to clinical covariates. CART analysis selected CICP, BAP, hemoglobin, and pain score for the final OS model, identifying five prognostic groups.

Elevated serum bone biomarker levels are associated with worse OS in bone-metastatic CRPC. Bone biomarkers can identify unique prognostic subgroups. These results further define the role of bone biomarkers in the design of CRPC trials.

Cancer treatment and research communications. 2018 Apr 28 [Epub]

P N Lara, M Plets, C Tangen, E Gertz, N J Vogelzang, M Hussain, P W Twardowski, M G Garzotto, J P Monk, M Carducci, A Goldkorn, P C Mack, I Thompson, M Van Loan, D I Quinn

University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States. Electronic address: ., SWOG Statistical Center, Seattle, WA, United States., US Department of Agriculture, Western Human Nutrition Research Center, University of California Davis, Davis, CA, United States., US Oncology, Las Vegas, NV, United States., Northwestern University, Chicago, IL, United States., City of Hope National Medical Center, Duarte, CA, United States., Oregon Health & Science University, Portland, OR, United States., Ohio State University, Columbus, OH, United States., Johns Hopkins University, Baltimore, MD, United States., USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States., University of California Davis Comprehensive Cancer Center, Sacramento, CA, United States., Cancer Therapy and Research Center, UTHSC, San Antonio, TX, United States.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe